Streetbeat News

MDGL

Madrigal Pharmaceuticals, Inc.

https://www.madrigalpharma.com

Industry

Biotechnology

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Open

355.00

Mkt cap

7.3B

Volume

257K

High

355.00

P/E Ratio

-13.44

52-wk high

368.29

Low

336.23

Div yield

N/A

52-wk low

189.00

Madrigal Pharmaceuticals will release its Q4 and full-year 2024 financial results on February 26, 2025, before the U.S. markets open.

Portfolio Pulse from

February 12, 2025 | 1:15 pm

Madrigal Pharmaceuticals' REZDIFFRA shows strong growth potential with $100-$103M in Q4 sales and a 61% growth rate. Despite potential competition, its first-mover advantage and combination use position it well. Analysts project $515M in 2025 sales, making MDGL stock a strong buy.

Portfolio Pulse from

January 19, 2025 | 2:45 pm

Madrigal Pharmaceuticals' stock fell nearly 20% this week despite positive preliminary financial results and bullish analyst updates, indicating high investor expectations.

Portfolio Pulse from

January 17, 2025 | 1:45 pm

Madrigal Pharmaceuticals' stock (MDGL) dropped by 10% due to disappointing preliminary Q4 sales figures for its drug Rezdiffra.

Portfolio Pulse from

January 15, 2025 | 4:00 pm

Madrigal Pharmaceuticals' stock is experiencing a significant decline, dropping 13.3% as of Monday morning.

Portfolio Pulse from

January 13, 2025 | 4:30 pm

Madrigal Pharmaceuticals provided a business update, revealing preliminary net sales for Q4 and full-year 2024, year-end cash, and the number of patients on Rezdiffra.

Portfolio Pulse from

January 13, 2025 | 12:00 pm

Madrigal Pharmaceuticals' drug Rezdiffra has had a strong launch, sparking buyout discussions. Despite competition, the potential for combination therapies and a future EU launch add interest for investors.

Portfolio Pulse from

January 09, 2025 | 11:30 am

Wall Street analysts have set an average price target for Madrigal Pharmaceuticals (MDGL) that suggests a potential upside of 26.4%. This optimism is supported by positive trends in earnings estimate revisions, which could lead to a stock price increase.

Portfolio Pulse from

November 18, 2024 | 4:15 pm

The article suggests investing $1,000 in a promising biotech stock, potentially Madrigal Pharmaceuticals (MDGL), and holding it for at least five years due to its bright future.

Portfolio Pulse from

November 10, 2024 | 2:45 pm

Madrigal Pharmaceuticals (MDGL) is highlighted as a strong momentum stock, suggesting it could be a top pick for momentum investors.

Portfolio Pulse from

November 07, 2024 | 6:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.